Company intelligence / Profile preview

Optomed

Ownership: Private
Employees: ~115
Development stage: Commercial

Overview

Optomed develops and markets handheld fundus cameras and integrated software solutions for eye disease screening. Its flagship product Aurora AEYE is the first FDA-cleared AI-enabled handheld fundus camera for instant diabetic retinopathy detection. Clinical studies show high sensitivity/specificity (>92%/89%) for diabetic retinopathy detection with over 99% imageability. The company’s platforms are used worldwide to improve access to early diagnosis of blinding diseases like diabetic retinopathy.

Therapeutic areas: Ophthalmology
Modalities: Device (Handheld fundus camera)Software (AI-enabled screening software)Artificial intelligence-based diagnostics
Industry: Medical Imaging

Partnerships

Volk Optical Inc.Carl Zeiss Meditec Inc.Haag-Streit DiagnosticsTopcon Medical Systems Inc.

Beyond the preview

Go deeper on Optomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optomed.

Explore the full profile